International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms.
International Consensus Classification
Myeloid and lymphoid neoplasms: Myeloproliferative neoplasms
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
02
09
2022
accepted:
16
12
2022
revised:
11
12
2022
pubmed:
30
12
2022
medline:
24
1
2023
entrez:
29
12
2022
Statut:
ppublish
Résumé
The recently published International Consensus Classification (ICC) of myeloid neoplasms summarized the results of an in-depth effort by pathologists, oncologists, and geneticists aimed to update the 2017 World Health Organization classification system for hematopoietic tumors. Along these lines, several important modifications were implemented in the classification of myeloproliferative neoplasms (MPNs). For chronic myeloid leukemia, BCR::ABL1-positive, the definition of accelerated and blast phase was simplified, and in the BCR::ABL1-negative MPNs, the classification was slightly updated to improve diagnostic specificity with a more detailed and better validated morphologic approach and the recommendation of more sensitive molecular techniques to capture in particular early stage diseases. In this regard, high sensitive single target (RT-qPCR, ddPCR) or multi-target next-generation sequencing assays with a minimal sensitivity of VAF 1% are now important for a proper diagnostic identification of MPN cases with low allelic frequencies at initial presentation. This review discusses the updated diagnostic criteria of MPN according to the ICC, particularly by highlighting the new concepts and how they can be applied in clinical settings to obtain an appropriate prognostic relevant diagnosis.
Identifiants
pubmed: 36580136
doi: 10.1007/s00428-022-03480-8
pii: 10.1007/s00428-022-03480-8
pmc: PMC9852206
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
53-68Informations de copyright
© 2022. The Author(s).
Références
Blood. 2016 Jun 2;127(22):2742-50
pubmed: 27006386
Blood Cancer J. 2015 Nov 13;5:e366
pubmed: 26565403
Leukemia. 2008 Jul;22(7):1299-307
pubmed: 18496562
Blood Cancer J. 2020 Feb 25;10(2):22
pubmed: 32098949
Histol Histopathol. 2005 Jan;20(1):317-28
pubmed: 15578448
Mayo Clin Proc. 2017 Jul;92(7):1118-1128
pubmed: 28688466
Leukemia. 2005 Feb;19(2):313-7
pubmed: 15549147
Br J Haematol. 2018 Aug;182(3):437-440
pubmed: 28695995
Eur J Haematol. 2016 Aug;97(2):145-54
pubmed: 26519944
Histol Histopathol. 1999 Oct;14(4):1241-56
pubmed: 10506940
Mod Pathol. 2012 Sep;25(9):1193-202
pubmed: 22627739
Curr Hematol Malig Rep. 2009 Jan;4(1):33-40
pubmed: 20425436
Blood. 2017 Jun 15;129(24):3142-3144
pubmed: 28620103
Leukemia. 2016 May;30(5):1126-32
pubmed: 26710883
Leukemia. 2016 Sep;30(9):1924-6
pubmed: 27125206
Mod Pathol. 2016 Aug;29(8):854-64
pubmed: 27174585
Int J Hematol. 2018 Oct;108(4):411-415
pubmed: 29987745
Am J Hematol. 2016 Oct;91(10):E454-5
pubmed: 27416333
Oncotarget. 2017 Oct 6;8(60):101735-101744
pubmed: 29254200
Haematologica. 2008 Nov;93(11):1645-51
pubmed: 18790799
Am J Hematol. 2017 Sep;92(9):885-891
pubmed: 28543356
Cancer. 2018 Oct 1;124(19):3849-3855
pubmed: 30321462
J Clin Oncol. 2011 Aug 10;29(23):3179-84
pubmed: 21747083
Mayo Clin Proc. 2019 Apr;94(4):599-610
pubmed: 30824279
Leukemia. 2018 May;32(5):1189-1199
pubmed: 29472717
Br J Haematol. 2020 Apr;189(2):291-302
pubmed: 31945802
Blood Adv. 2016 Nov 22;1(1):21-30
pubmed: 29296692
Ann Intern Med. 2018 Mar 6;168(5):317-325
pubmed: 29335713
Blood Cancer J. 2018 Feb 15;8(2):21
pubmed: 29449543
BMC Cancer. 2019 Feb 28;19(1):184
pubmed: 30819138
Blood. 2017 Jun 15;129(24):3227-3236
pubmed: 28351937
Haematologica. 2018 Sep;103(9):e392-e394
pubmed: 29622658
Leukemia. 2013 Sep;27(9):1874-81
pubmed: 23739289
Leuk Lymphoma. 2000 Jan;36(3-4):295-308
pubmed: 10674901
Am J Hematol. 2016 May;91(5):503-6
pubmed: 26890983
N Engl J Med. 2017 Mar 9;376(10):917-927
pubmed: 28273028
N Engl J Med. 2019 Nov 28;381(22):2135-2144
pubmed: 31774958
Blood. 2011 May 26;117(21):5710-8
pubmed: 21447832
Blood. 2011 Jun 2;117(22):5857-9
pubmed: 21490340
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):122-128
pubmed: 34889372
Leuk Res. 2015 May;39(5):525-9
pubmed: 25840747
Blood Cancer J. 2020 Oct 14;10(10):100
pubmed: 33056979
Mod Pathol. 2017 Feb;30(2):169-179
pubmed: 27739437
J Hematol Oncol. 2019 Dec 5;12(1):131
pubmed: 31801582
Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11746-50
pubmed: 8524841
PLoS One. 2017 Oct 31;12(10):e0185602
pubmed: 29088303
Leukemia. 2021 Dec;35(12):3339-3351
pubmed: 34480106
Leukemia. 2014 Dec;28(12):2292-9
pubmed: 25212276
Am J Hematol. 2017 May;92(5):417-419
pubmed: 28196400
Am J Hematol. 2020 Feb;95(2):212-224
pubmed: 31769070
Leukemia. 2010 Sep;24(9):1574-9
pubmed: 20631743
Fac Rev. 2021 Apr 1;10:35
pubmed: 33977288
Blood Cancer J. 2018 Nov 7;8(11):104
pubmed: 30405096
Am J Hematol. 2015 Jul;90(7):653-6
pubmed: 25850813
Am J Hematol. 2017 Apr;92(4):E48-E51
pubmed: 28109016
Am J Hematol. 2021 Nov 1;96(11):1472-1480
pubmed: 34424575
Best Pract Res Clin Haematol. 2006;19(3):571-93
pubmed: 16781489
Am J Hematol. 2020 Dec;95(12):1599-1613
pubmed: 32974939
Blood. 2022 Sep 15;140(11):1200-1228
pubmed: 35767897
Br J Haematol. 2021 May;193(4):792-797
pubmed: 33751548